Maze Therapeutics, Inc. Common Stock (MAZE) Stock Price, Quote & AI Analysis

Live MAZE stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Maze Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Maze Therapeutics, Inc. Common Stock (MAZE), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

MAZE
Maze Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
43.560000
High
47.320000
Low
42.941300
Volume
741,872
VWAP
-
Market Cap
$2,097,045,369.52
52W Range
$6.71 - $47.36
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Maze Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Maze Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Company Details
Market Cap
$2.24B
Shares Outstanding
48,119,448
Weighted Shares Outstanding
48,119,444
CEO
Jason V. Coloma
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Employees
125
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Maze Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...